A promising experimental skin cancer vaccine developed by Moderna and Merck shows strong anti-tumour effects and survival benefits for advanced melanoma patients after five years of clinical trials. The therapy combines mRNA technology with Merck's Keytruda, reducing cancer recurrence risk by 49%. The companies await phase three trial results to confirm benefits for high-risk melanoma patients. Teljes cikk (Euronews.com)